Related Content
- Pfizer forms licensing agreement with Seattle Genetics
- Novartis announces merger proposal for Alcon
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- PhRMA: Nearly 300 preventive medicines for heart disease, stroke in development
- Novartis positions itself as eye care giant with Alcon merger
PITTSBURGH — Mylan has launched a generic treatment for breast cancer, the drug maker said Monday.
Mylan announced the launch of letrozole tablets in the 2.5-mg strength, an adjuvant treatment for postmenopausal women with hormone receptor-positive early-stage breast cancer.
The drug is the first generic version of Novartis’ Femara, which had sales of about $682 million in 2010, according to IMS Health.
